Mayne Pharma Group Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mayne Pharma Group Limited
Significant change is brewing at Mayne Pharma, with the Australian firm announcing the proposed sale of its US-based CDMO business for nearly half-a-billion dollars. At the same time, long time CEO Scott Richards is heading for the exit door.
While Israel Makov steps away from Sun Pharmaceuticals, Mayne and Avet bring in new executives, Amneal appoints a new director and the AAM promotes a loyal colleague.
Carbogen, Advanz and Perrigo have all announced significant changes to their C-suite staff, while several firms have announced changes to their executive and advisory boards.
Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.
- Contract Research Organization-CRO
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
- Controlled Release
Drug Discovery Technologies
- Natural Products
- Molecular Diversity
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Halcygen Pharmaceuticals
- Mayne Pharma International
- Mayne Pharma Ventures Pty Ltd
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.